Adaptimmune up as cancer therapy meets main goal in mid-stage study

Adaptimmune Therapeutics

13/11/2024 15:20

** Shares of drug developer Adaptimmune Therapeutics
 ADAP.O  rise ~3% to 81 cents    
    ** Co says its cell therapy being developed to treat two
rare types of cancers met the main goal of a mid-stage study
    ** The therapy, lete-cel, helped 42% of study patients
achieve partial or complete response to the treatment - ADAP
    ** Co plans to begin application process for lete-cel in
2025 for the treatment of both synovial sarcoma and myxoid/round
cell liposarcoma (MRCLS) - ADAP  
    ** Synovial sarcoma is a cancer in the soft tissues that
most often affects young people and MRCLS is a cancer that grows
in the cells that store fat in the body
    ** Including session gains, stock up ~2% YTD

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))